Novaliq Announces Positive Topline Results for Its SEECASE Phase 2 Trial of NOV03 for the Treatment of Patients with Dry Eye Disease
HEIDELBERG, Germany--(BUSINESS WIRE)--#CyclASol--Novaliq, a specialty pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free technology for ophthalmology, today announces positive topline results for its SEECASE phase 2 clinical trial of NOV03 for the treatment of dry eye disease (DED) in more than 300 patients. NOV03 (100% perfluorohexyloctane) is a preservative-free ophthalmic solution and the firs